SK Bioscience Co Ltd

Price Chart

Risk-Adjusted Performance

SK Bioscience Co Ltd (302440) Price Performance

SK Bioscience Co Ltd (302440) trades on KO in KRW. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at KRW42000.00, down 0.36% from the previous close.

Over the past year, 302440 has traded between a low of KRW38500.00 and a high of KRW60100.00. The stock has gained 6.9% over this period. It is currently 30.1% below its 52-week high.

SK Bioscience Co Ltd has a market capitalization of $3.31T.

About SK Bioscience Co Ltd

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea. SK bioscience Co.,Ltd. is a subsidiary of SK Chemicals Co.,Ltd.